Novo Nordisk A/S

- Novo Nordisk has not specifically announced any new fundraising through debt or equity in the provided report. - The company plans capital expenditure (CapEx) around DKK 55 billion in 2026, with expectations for CapEx to decline in coming years following project completions. - They approved a new share repurchase program of up to DKK 15 billion over the next 12 months, indicating a use of capital to return value to shareholders rather than raise new equity. - Cash flow from operations was strong (close to DKK 120 billion in 2025), with significant cash returns to shareholders via dividends and share buybacks. - No explicit mention of issuing new debt or equity for fundraising purposes was made in the call. Overall, Novo Nordisk appears well-capitalized and is focused on organic investments and shareholder returns rather than raising new funds through debt or equity.

- Capital expenditure (CapEx) guidance for 2026 is expected to be around DKK 55 billion. - CapEx investments are focused on manufacturing capacity expansion, including major API (active pharmaceutical ingredient) facilities. - Novo Nordisk expects some new major API facilities to come online during 2026, with more expansions in subsequent years. - Capital expenditure investments are anticipated to decline in the coming years following the finalization of expansion projects. - Over DKK 60 billion was spent on manufacturing capacity expansion through CapEx in 2025. - Novo Nordisk also allocates around DKK 30 billion towards expanding its R&D pipeline through business development. - The company has approved a new share repurchase program of up to DKK 15 billion to be executed over the next 12 months. - Strategic aspirations are being updated, with new plans to be introduced at the Capital Market Day in September 2026.

- 2026 sales growth is expected to be negative, with adjusted sales growth projected at -5% to -13% at constant exchange rates, reflecting price declines and market challenges. - International Operations are expected to grow at low single-digit rates, supported by ongoing GLP-1 volume growth and market expansion, despite some patent expiries and increased competition. - U.S. operations anticipate a significant sales decline in the teens, driven primarily by price reductions, competition, market access investments, and the impact of the Most Favored Nations (MFN) agreement. - The global GLP-1 market is still expanding, with continued volume growth projected due to increased patient reach, particularly in obesity and diabetes care. - Novo Nordisk expects volume expansion to partially offset price declines, especially with the uptake of the Wegovy pill. - Longer-term optimism is linked to the success of products like the Wegovy pill and ongoing regulatory milestones across therapy areas.

- Novo Nordisk expects adjusted sales growth in 2026 to be between -5% to -13% at constant exchange rates, reflecting pricing headwinds, market dynamics, and competition. - Adjusted operating profit growth for 2026 is also projected in the range of -5% to -13% at constant exchange rates. - Reported growth in Danish kroner is expected to be about 3 percentage points (sales) and 5 percentage points (operating profit) lower than at constant exchange rates due to currency exchange effects. - Sales growth outlook factors in volume expansion in International Operations (mid-single-digit growth), offset by steep price declines and market competition in the U.S. (teens percentage decline). - The company anticipates ongoing investments in market access and volume growth, especially with the Wegovy pill uptake and Medicare coverage improvements starting mid-2026. - Novo Nordisk expects positive free cash flow of DKK 35-45 billion in 2026. - No specific EPS guidance disclosed, but profit outlook aligns with sales and operating profit guidance.

The provided pages in the PDF do not explicitly mention any details about Novo Nordisk's current or expected orderbook or pending orders. The content focuses primarily on: - Executive management changes and future outlook. - Market growth, especially in obesity and diabetes care. - Launches and uptake of products like Wegovy (pill and injectable). - Guidance for 2026 including sales expectations and strategic priorities. - Supply confidence for Wegovy pill with no anticipated outages in 2026. - Financial metrics such as sales, operating profit, and dividend plans. No direct information related to orderbook or pending order volumes is disclosed in the available transcript.